Orbimed Advisors LLC Acquires 1,477,450 Shares of Lexeo Therapeutics, Inc. $LXEO

Orbimed Advisors LLC boosted its stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 69.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,602,450 shares of the company’s stock after purchasing an additional 1,477,450 shares during the period. Orbimed Advisors LLC’s holdings in Lexeo Therapeutics were worth $20,678,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of LXEO. Affinity Asset Advisors LLC raised its position in Lexeo Therapeutics by 57.8% during the 1st quarter. Affinity Asset Advisors LLC now owns 5,050,211 shares of the company’s stock worth $28,988,000 after purchasing an additional 1,850,211 shares during the last quarter. RA Capital Management L.P. bought a new stake in shares of Lexeo Therapeutics in the 4th quarter valued at about $49,650,000. Paradigm Biocapital Advisors LP bought a new stake in shares of Lexeo Therapeutics in the 4th quarter valued at about $47,299,000. Vestal Point Capital LP grew its position in shares of Lexeo Therapeutics by 37.7% in the 4th quarter. Vestal Point Capital LP now owns 4,475,000 shares of the company’s stock valued at $44,437,000 after buying an additional 1,225,000 shares during the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Lexeo Therapeutics in the second quarter valued at about $16,117,000. 60.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently commented on LXEO. Chardan Capital reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Lexeo Therapeutics in a research note on Monday, May 11th. Wall Street Zen raised shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. JPMorgan Chase & Co. lowered their price target on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a report on Thursday, June 25th. Finally, Weiss Ratings upgraded shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $18.75.

Lexeo Therapeutics Stock Performance

Shares of Lexeo Therapeutics stock opened at $4.66 on Monday. The business has a 50-day moving average price of $4.75 and a two-hundred day moving average price of $6.00. Lexeo Therapeutics, Inc. has a 1-year low of $3.60 and a 1-year high of $10.99. The company has a market cap of $365.90 million, a P/E ratio of -3.21 and a beta of 1.42.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.04. Equities research analysts forecast that Lexeo Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Insider Activity at Lexeo Therapeutics

In other Lexeo Therapeutics news, insider Narinder Pal Bhalla sold 22,306 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $4.42, for a total value of $98,592.52. Following the transaction, the insider directly owned 82,194 shares of the company’s stock, valued at approximately $363,297.48. The trade was a 21.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Richard Nolan Townsend sold 25,947 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.48, for a total value of $116,242.56. Following the completion of the transaction, the chief executive officer directly owned 377,817 shares in the company, valued at approximately $1,692,620.16. This trade represents a 6.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 62,204 shares of company stock valued at $280,089 in the last ninety days. 2.00% of the stock is currently owned by insiders.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc is a clinical?stage biotechnology company dedicated to developing novel, precision?designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next?generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.